Nextone Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-12-2024
- Paid Up Capital ₹ 0.80 M
as on 30-12-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 243.07%
(FY 2022)
- Profit 17.44%
(FY 2022)
- Ebitda 32.60%
(FY 2022)
- Net Worth -170.95%
(FY 2022)
- Total Assets 2.88%
(FY 2022)
About Nextone Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Durgesh Tripathi and Dhirender Tripathi serve as directors at the Company.
- CIN/LLPIN
U51909UP2020PTC135071
- Company No.
135071
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Sep 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nextone Pharmaceuticals Private Limited offer?
Nextone Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Protein Powder, Multivitamin Tablets & Capsules, Mineral Supplement.
Who are the key members and board of directors at Nextone Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Durgesh Tripathi  | Director | 23-Sep-2020 | Current |
| Dhirender Tripathi | Director | 23-Sep-2020 | Current |
Financial Performance of Nextone Pharmaceuticals.
Nextone Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 243.07% increase. The company also saw a substantial improvement in profitability, with a 17.44% increase in profit. The company's net worth observed a substantial decline by a decrease of 170.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nextone Pharmaceuticals?
Unlock access to Nextone Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nextone Pharmaceuticals?
Nextone Pharmaceuticals has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nextone Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nextone Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.